Publicaciones en colaboración con investigadores/as de University College London (18)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

2023

  1. Assessment of Pre-Clinical Liver Models Based on Their Ability to Predict the Liver-Tropism of Adeno-Associated Virus Vectors

    Human gene therapy, Vol. 34, Núm. 7-8, pp. 273-288

2022

  1. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions

    Gut, Vol. 71, Núm. 8, pp. 1669-1683

2021

  1. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

    JHEP Reports, Vol. 3, Núm. 3

  2. Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: Dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis

    Gut, Vol. 70, Núm. 2, pp. 388-400

2020

  1. Dual pharmacological targeting of hdacs and pde5 inhibits liver disease progression in a mouse model of biliary inflammation and fibrosis

    Cancers, Vol. 12, Núm. 12, pp. 1-27

  2. Exogenous Liposomal Ceramide-C6 Ameliorates Lipidomic Profile, Energy Homeostasis, and Anti-Oxidant Systems in NASH

    Cells, Vol. 9, Núm. 5

2019

  1. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

    The Lancet Oncology, Vol. 20, Núm. 10, pp. e566-e581

  2. Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis

    Nature Communications, Vol. 10, Núm. 1

  3. Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma

    Hepatology, Vol. 69, Núm. 2, pp. 587-603

  4. Effect of risk of malnutrition on 30-day mortality among older patients with acute heart failure in Emergency Departments

    European Journal of Internal Medicine, Vol. 65, pp. 69-77

2018

  1. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Annals of Oncology, Vol. 29, pp. iv238-iv255

  2. Intratumoral immunotherapy with XCL1 and sFlt3L encoded in recombinant semliki forest virus–derived vectors fosters dendritic cell–mediated t-cell cross-priming

    Cancer Research, Vol. 78, Núm. 23, pp. 6643-6654

2017

  1. PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity

    Cell Reports, Vol. 20, Núm. 8, pp. 1818-1829

2016

  1. Complementary effects of interleukin-15 and alpha interferon induce immunity in hepatitis B virus transgenic mice

    Journal of Virology, Vol. 90, Núm. 19, pp. 8563-8574

2015

  1. A core of kinase-regulated interactomes defines the neoplastic MDSC lineage

    Oncotarget, Vol. 6, Núm. 29, pp. 27160-27175

2012

  1. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: Proposal for a subclassification to facilitate treatment decisions

    Seminars in Liver Disease, Vol. 32, Núm. 4, pp. 348-359